Insights into NEK2 inhibitors as antitumor agents: From mechanisms to potential therapeutics

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• NEK2 (NIMA-related kinase 2) is a serine/threonine kinase vital for mitotic processes.
• Overexpression of NEK2 is linked to centrosome amplification and chromosomal instability in various cancers.
• This overexpression contributes to tumor development and therapeutic resistance.

Purpose of the Study:

• To review the chemical structures, biological functions, and cancer associations of NEK2.
• To summarize current small molecule NEK2 inhibitors, including structure-activity relationships and limitations.
• To provide insights for developing novel NEK2 inhibitors and overcoming clinical translation challenges.

Main Methods:

• Literature review of NEK2 functions and inhibitors.
• Analysis of structure-activity relationships for small molecule inhibitors.
• Discussion of research strategies and clinical translation hurdles.

Main Results:

• NEK2 plays a critical role in cell division and its dysregulation is oncogenic.
• Several small molecule inhibitors targeting NEK2 have been developed, but none have reached clinical trials.
• Limitations in current inhibitors necessitate optimized design and innovative approaches.

Conclusions:

• Targeting NEK2 is a promising anti-cancer strategy.
• Further research is needed to develop clinically viable NEK2 inhibitors.
• Overcoming challenges in drug design and development is crucial for therapeutic success.